The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Geraldine Helen O'Sullivan Coyne
No Relationships to Disclose
 
Nancy Moore
Patents, Royalties, Other Intellectual Property - Nestle Nutrition
 
Elad Sharon
No Relationships to Disclose
 
Naoko Takebe
No Relationships to Disclose
 
Kristin K. Fino
No Relationships to Disclose
 
Katherine V. Ferry-Galow
No Relationships to Disclose
 
James S. Hu
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Research Funding - Merck
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - TRACON Pharma
 
William L. Read
No Relationships to Disclose
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi Sankyo; Deciphera; Ignyta; Loxo; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); NanoCarrier (Inst); Philogen (Inst); Plexxikon (Inst); Roche/Genentech (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Ignyta; NanoCarrier
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice
 
John Glod
No Relationships to Disclose
 
Anthony Paul Conley
Consulting or Advisory Role - Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Ignyta (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); NantHealth (Inst)
Travel, Accommodations, Expenses - Genentech
 
Jared C. Foster
No Relationships to Disclose
 
Laura K. Fogli
No Relationships to Disclose
 
Ralph E. Parchment
Employment - Leidos Biomedical Research
Stock and Other Ownership Interests - Leidos; SciTech Development LLC
Patents, Royalties, Other Intellectual Property - Cambridge University Press for The Biological Basis of Cancer; Named Inventor on US Patent 9,644,037; Named inventor on US Patent US8709379 B2
Travel, Accommodations, Expenses - Sanofi/Aventis
 
James H. Doroshow
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose